Relative Bioavailability
Conditions
Keywords
Pharmacokinetics, Inhaled corticosteroid
Brief summary
This study is to compare the systemic exposure of budesonide delivered by the combination inhaler (budesonide/albuterol sulfate pressurized inhalation suspension \[BDA metered dose inhaler {BDA MDI}\]) with Pulmicort Flexhaler dry-powder inhaler (DPI).
Detailed description
This study will be an open-label, randomized, 2-way cross-over study in healthy adult male or female participants, performed at a single study center.Participants will receive single doses of BDA MDI or Pulmicort Flexhaler on 2 occasions, under fasted conditions. There will be a minimum washout period of 3 days between each dose administration. A total of 66 participants will be randomized in this study to ensure that at least 62 participants are evaluable. The study will comprise of screening period of maximum 27 days; Two treatment periods during which participants will be resident from the day prior to administration of budesonide/albuterol sulfate pressurized inhalation suspension metered dose inhaler (BDA MDI) or Pulmicort Flexhaler (Day -1) until at least 24 hours after dosing. Participants will be discharged on the morning of Day 2; and a final follow-up visit within 5 to 7 days after the last administration of BDA MDI or Pulmicort Flexhaler.
Interventions
DRUGBDA MDI 160/180 mcg
Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.
DRUGPulmicort Flexhaler 180 mcg
Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provision of signed and dated, written informed consent prior to any study specific procedures. 2. Healthy male and female participants aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture. 3. Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit, must not be lactating. 4. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive. 5. Must be able to demonstrate proper inhalation technique using the Vitalograph Aerosol Inhalation Monitor (AIM) device 3 repeated times as well as be able to use the BDA MDI and Pulmicort Flexhaler devices according to instructions. 6. Forced expiratory volume in 1 second in liters (FEV1) ≥80% of predicted value and FEV1/forced vital capacity in liters (FVC) ratio ≥70%.
Exclusion criteria
1. Pregnant or nursing female participants or participants who are trying to conceive 2. For female participants, a positive serum human chorionic gonadotropin (hCG) test at the Screening Visit or a positive urine hCG at admission for any of the 2 Treatment Periods. 3. History of any clinically significant disease or disorder which, in the opinion of the PI, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study. 4. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. 5. Participants who have cancer that has not been in complete remission for at least 5 years. 6. Any history of asthma or Chronic obstructive pulmonary disease (COPD). 7. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP. 8. Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results at the Screening Visit, as judged by the PI. 9. Any clinically significant abnormal findings in vital signs at the Screening Visit, as judged by the PI. 10. Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) at the Screening Visit, as judged by the PI. 11. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody. 12. Known or suspected history of alcohol or drug abuse, or excessive intake of alcohol, in past 2 years, as judged by the PI. 13. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest. 14. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to the Screening Visit. 15. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to budesonide, albuterol sulfate and any component of the MDI and DPI. 16. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening. 17. Positive screen for drugs of abuse, cotinine or alcohol at the Screening Visit or on each admission to the Clinical Unit. 18. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP. 19. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life. 20. Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives. 21. Judgment by the PI that the participant should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements. 22. Vulnerable participants, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area under plasma concentration-time curve from time zero to infinity (AUC) for budesonide | On Day 1 (Pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose) and on Day 2 (24 hours post-dose) | To compare the systemic exposure of budesonide after single-dose administration of BDA MDI versus Pulmicort Flexhaler |
| Area under the plasma concentration-curve from time zero to time of last quantifiable concentration [AUC(0-t)] for budesonide | On Day 1 (Pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose) and on Day 2 (24 hours post-dose) | To compare the systemic exposure of budesonide after single-dose administration of BDA MDI versus Pulmicort Flexhaler |
| Maximum observed plasma concentration (Cmax) for budesonide | On Day 1 (Pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose) and on Day 2 (24 hours post-dose) | To compare the systemic exposure of budesonide after single-dose administration of BDA MDI versus Pulmicort Flexhaler |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Terminal elimination rate constant (λz) | On Day 1 (Pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose) and on Day 2 (24 hours post-dose) | To determine λz for budesonide delivered by BDA MDI and Pulmicort Flexhaler |
| Apparent total body clearance of drug from plasma after extravascular administration (CL/F) | On Day 1 (Pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose) and on Day 2 (24 hours post-dose) | To determine CL/F for budesonide delivered by BDA MDI and Pulmicort Flexhaler |
| Time to reach maximum observed plasma concentration (tmax) | On Day 1 (Pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose) and on Day 2 (24 hours post-dose) | To determine tmax for budesonide delivered by BDA MDI and Pulmicort Flexhaler |
| Number of participants with adverse events and serious adverse events | From screening (Day -27 to Day -2) to post study visit ( 5-7 days) | To assess the safety and tolerability of BDA MDI and Pulmicort Flexhaler |
| Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) | On Day 1 (Pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose) and on Day 2 (24 hours post-dose) | To determine Vz/F for budesonide delivered by BDA MDI and Pulmicort Flexhaler |
| Time of last quantifiable plasma concentration (tlast) | On Day 1 (Pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose) and on Day 2 (24 hours post-dose) | To determine tlast for budesonide delivered by BDA MDI and Pulmicort Flexhaler |
| Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz) | On Day 1 (Pre-dose and 5, 15, 20, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 10 and 12 hours post dose) and on Day 2 (24 hours post-dose) | To determine t½λz for budesonide delivered by BDA MDI and Pulmicort Flexhaler |
Countries
United States
Outcome results
None listed